FLT3 (ITD)-NPOS

FLT3 · Variant type: fusion · HGVS: p.L610_E611insCSSDNEYFYVDFREYEYDLKWEF-PRENL · Fusion partner: NPOS (ITD)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Fostamatinib	99.0%	1.0%	96.74
2	Brigatinib	98.6%	1.4%	82.96
3	Gilteritinib	98.4%	1.6%	88.97
4	Ponatinib	98.1%	1.9%	78.23
5	Pacritinib	97.3%	2.7%	88.64
6	Defactinib	96.7%	3.3%	92.68
7	Sunitinib	96.6%	3.4%	91.73
8	Pralsetinib	95.2%	4.8%	93.43
9	Quizartinib	94.1%	5.9%	99.50
10	Nintedanib	91.4%	8.6%	90.23
11	Fedratinib	90.8%	9.2%	96.21
12	Selpercatinib	88.8%	11.2%	96.72
13	Sorafenib	88.5%	11.6%	96.72
14	Avapritinib	88.2%	11.8%	97.73
15	Entrectinib	87.9%	12.1%	93.69
16	Canertinib	81.7%	18.3%	96.49
17	Alectinib	81.4%	18.6%	95.49
18	Tenalisib	77.7%	22.3%	97.98
19	Cabozantinib	75.0%	25.0%	92.73
20	Alpelisib	71.7%	28.3%	97.22
21	Erlotinib	67.1%	32.9%	99.75
22	Rabusertib	65.8%	34.2%	98.74
23	Ripretinib	60.6%	39.4%	92.95
24	Pexidartinib	58.1%	41.9%	99.49
25	Pazopanib	51.9%	48.1%	97.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Fostamatinib	99.0%	97.2%	+1.7%
Brigatinib	98.6%	98.1%	+0.5%
Gilteritinib	98.4%	99.2%	-0.8%
Ponatinib	98.1%	97.9%	+0.2%
Pacritinib	97.3%	93.6%	+3.7%
Defactinib	96.7%	94.6%	+2.1%
Sunitinib	96.6%	98.7%	-2.1%
Pralsetinib	95.2%	97.6%	-2.4%
Quizartinib	94.1%	97.9%	-3.8%
Nintedanib	91.4%	95.2%	-3.8%
Fedratinib	90.8%	98.2%	-7.4%
Selpercatinib	88.8%	96.1%	-7.3%
Sorafenib	88.5%	97.3%	-8.9%
Avapritinib	88.2%	88.6%	-0.3%
Entrectinib	87.9%	96.1%	-8.2%
Canertinib	81.7%	86.3%	-4.6%
Alectinib	81.4%	84.5%	-3.1%
Tenalisib	77.7%	—	—
Cabozantinib	75.0%	95.0%	-20.0%
Alpelisib	71.7%	—	—
Erlotinib	67.1%	—	—
Rabusertib	65.8%	—	—
Ripretinib	60.6%	—	—
Pexidartinib	58.1%	—	—
Pazopanib	51.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 37.1ms